Dr. Hohl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 University Dr
Hershey, PA 17033Phone+1 717-531-4034Fax+1 717-531-0002
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1989 - 1991- University of ChicagoFellowship, Hematology and Medical Oncology, 1987 - 1989
- University of ChicagoResidency, Internal Medicine, 1984 - 1987
Rush Medical College of Rush University Medical CenterClass of 1984
Certifications & Licensure
PA State Medical License 2014 - 2024
IA State Medical License 1991 - 2014
IL State Medical License 1984 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML Start of enrollment: 2001 Jun 01
- A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer Start of enrollment: 2003 Aug 01
- Safety Study of GPX-150 in Patients With Solid Tumors Start of enrollment: 2008 Jan 01
Publications & Presentations
PubMed
- 728 citationsA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW. K. A. Yung, Robert E. Albright, Jeffrey J. Olson, R Fredericks, Karen Fink
British Journal of Cancer. 2000-09-01 - 61 citationsA Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer PatientsEdward M. Messing, Jason R. Gee, Daniel Saltzstein, KyungMann Kim, P. Anthony Disant’Agnese
Cancer Prevention Research. 2012-04-01 - 23 citationsIs there a future for prenyltransferase inhibitors in cancer therapySarah A. Holstein, Raymond J. Hohl
Current Opinion in Pharmacology. 2012-12-01
Journal Articles
- Inhibiting Geranylgeranyl Diphosphate Synthesis Reduces Nuclear Androgen Receptor Signaling and Neuroendocrine Differentiation in Prostate Cancer Cell ModelsRaymond Hohl, MD, The Prostate
Press Mentions
Machtay Named Cancer Institute Associate Director for Clinical ResearchSeptember 29th, 2020- Penn State Cancer Institute Joins Caris Life Sciences' Precision Oncology AllianceAugust 25th, 2020
Hershey Medical Center Names New Radiation Oncology ChairMarch 7th, 2019- Join now to see all
Grant Support
- Career Development ProgramNational Cancer Institute2007–2011
- Cell Signaling And Developmental PharmacologyNational Cancer Institute2009
- Cell SignalingNational Cancer Institute2005
- Core--Analytical Pharmacology LaboratoryNational Cancer Institute2003
- Trial Of Irinotecan In PTS With Abnormal Liver/Renal Function Or Prior Pelvic RADNational Center For Research Resources2000–2002
- Phase I Trial Of Perillyl Alcohol AdminstrationNational Center For Research Resources1998–2000
- Phase I Study Of Taxol For Patients With Primary Or Metastatic Liver TumorsNational Center For Research Resources1996
- High Dose Lovastatin For Treatment Of RAS Oncogene Associated MalignanciesNational Center For Research Resources1996
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
